Overview

Study of Colon GVAX and Cyclophosphamide in Patients With Metastatic Colorectal Cancer

Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and feasibility of vaccination with two irradiated allogeneic colorectal carcinoma cells administered with a GM-CSF producing bystander cell line in sequence with an immunomodulatory dose of Cyclophosphamide
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborator:
National Cancer Institute (NCI)
Treatments:
Cyclophosphamide
Molgramostim
Sargramostim
Vaccines